National reference centre for Staphylococcus aureus and other species, Department of microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Université libre de Bruxelles, Brussels, Belgium.
Department of microbiology, Algemeen Medisch Laboratorium (AML), Antwerp, Belgium.
Euro Surveill. 2024 May;29(19). doi: 10.2807/1560-7917.ES.2024.29.19.2300668.
BackgroundAntimicrobial resistance to mupirocin and fusidic acid, which are used for treatment of skin infections caused by is of concern.AimTo investigate resistance to fusidic acid and mupirocin in meticillin-susceptible (MSSA) from community-acquired skin and soft tissue infections (SSTIs) in Belgium.MethodsWe collected 2013-2023 data on fusidic acid and mupirocin resistance in SSTI-associated MSSA from two large Belgian laboratories. Resistant MSSA isolates sent to the Belgian Reference Centre were -typed and analysed for the presence of the and virulence genes and the resistance gene. In addition, we whole genome sequenced MSSA isolates collected between October 2021 and September 2023.ResultsMupirocin resistance increased between 2013 and 2023 from 0.5-1.5% to 1.7-5.6%. Between 2018 and 2023, 91.4% (64/70) of mupirocin-resistant isolates were co-resistant to fusidic acid. By September 2023, between 8.9% (15/168) and 10.1% (11/109) of children isolates from the two laboratories were co-resistant. Of the 33 sequenced isolates, 29 were sequence type 121, clonal and more distantly related to the European epidemic fusidic acid-resistant impetigo clone (EEFIC) observed in Belgium in 2020. These isolates carried the and genes conferring resistance to mupirocin and fusidic acid, respectively, and the and virulence genes.ConclusionWe highlight the spread of a mupirocin-resistant EEFIC in children, with a seasonal trend for the third quarter of the year. This is of concern because this variant is resistant to the two main topical antibiotics used to treat impetigo in Belgium.
背景
对用于治疗 引起的皮肤感染的莫匹罗星和夫西地酸的抗药性令人担忧。
目的
调查比利时社区获得性皮肤和软组织感染（SSTI）中耐甲氧西林金黄色葡萄球菌（MSSA）对夫西地酸和莫匹罗星的耐药性。
方法
我们收集了 2013 年至 2023 年来自比利时两个大型实验室的与 SSTI 相关的 MSSA 中夫西地酸和莫匹罗星耐药的数据。送到比利时参考中心的耐药 MSSA 分离株进行了 分型，并分析了 基因和 基因以及 耐药基因的存在情况。此外，我们对 2021 年 10 月至 2023 年 9 月期间收集的 MSSA 分离株进行了全基因组测序。
结果
莫匹罗星耐药性从 2013 年至 2023 年从 0.5-1.5%增加到 1.7-5.6%。2018 年至 2023 年，91.4%（64/70）的莫匹罗星耐药分离株对夫西地酸也耐药。到 2023 年 9 月，两个实验室的儿童分离株中分别有 8.9%（15/168）和 10.1%（11/109）为双重耐药。33 株测序分离株中，29 株为 121 型序列型，克隆且与 2020 年在比利时观察到的欧洲流行的夫西地酸耐药脓疱疮克隆（EEFIC）更为遥远。这些分离株携带 基因和 基因，分别赋予对莫匹罗星和夫西地酸的耐药性，以及 基因和 基因的毒力。
结论
我们强调了在儿童中传播的一种对莫匹罗星耐药的 EEFIC，具有第三季度的季节性趋势。这令人担忧，因为这种变体对在比利时用于治疗脓疱疮的两种主要局部抗生素都有耐药性。
